Neurocrine Biosciences discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders. Products include INGREZZA, ALKINDI, Efmody, Orilissa, and Oriahnn. Product candidates in clinical development target various conditions, such as dyskinetic cerebral palsy, developmental encephalopathy syndrome, and major depressive disorder. The company has collaborations with multiple pharmaceutical companies, including Heptares Therapeutics, Takeda Pharmaceutical, and AbbVie Inc. Neurocrine was incorporated in 1992 and is headquartered in San Diego, California.
| Indicator | Value |
|---|---|
| PER | 38.4 |
| EV/EBITDA | 19.0 |
| Price/Free Cash Flow' | 23.6 |
| ROIC | 19.6% |
| Net Debt/EBITDA | 0.3 |